Overexpression of LCN2 has been associated with increased cancer cell motility, epithelial-to-mesenchymal transition (EMT), proliferation, angiogenesis, invasion, and metastasis in aggressive cancers, including pancreatic, esophageal, and breast cancer [12,13]. This evidence concerns the gene LCN2 and cancer.